CJC-1295 and ipamorelin are the two most frequently paired compounds in growth hormone (GH) axis research — yet rarely explained together at the level of mechanism. Both stimulate the pituitary gland to release growth hormone, but through entirely different receptors: one mimics the hypothalamic signal (GHRH), the other mimics the stomach-derived signal (ghrelin).

Ver materiales de investigación: Tienda VONOX Labs

Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not intended for human or veterinary consumption. This information is provided for educational purposes only and is not medical advice.

Two Compounds, Two Pathways: At a Glance

	CJC-1295	Ipamorelin
Receptor target	GHRH receptor (GHRHR) on pituitary somatotrophs	Ghrelin receptor (GHS-R1a) on pituitary somatotrophs and hypothalamic neurons
Peptide size/class	29-amino-acid GHRH analog (tetrasubstituted GHRH 1–29)	Pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2, ~712 Da); growth hormone secretagogue
Developer origin	ConjuChem Biotechnologies, early 2000s	Novo Nordisk (as NNC 26-0161), late 1990s
Half-life profile	DAC form: ~6–8 days via serum-albumin binding; non-DAC (Mod GRF 1-29): minutes	Minutes — a short-acting secretagogue
Selectivity notes	Acts through the pituitary; somatostatin-mediated feedback loops remain engaged	High GH selectivity: minimal ACTH, cortisol, prolactin, or aldosterone stimulation at GH-releasing doses
Human evidence level	Early-phase pharmacology only: short studies in healthy adults (mid-2000s)	Early-phase pharmacology plus early investigation for postoperative gastrointestinal recovery
Regulatory status	Not FDA approved; development program discontinued	Not FDA approved; development program discontinued

What Is CJC-1295?

CJC-1295 is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH) — the hypothalamic hormone that commands the pituitary to release growth hormone. Developed by ConjuChem in the early 2000s, it is based on GHRH(1-29) — the shortest fully active fragment of the natural hormone — with four substitutions (positions 2, 8, 15, and 27) resisting the proteases that destroy natural GHRH within minutes.

Two research forms exist, and confusing them is the most common error in discussions of this compound:

• CJC-1295 DAC (Drug Affinity Complex) — the original ConjuChem design, carrying a maleimide group that covalently binds circulating serum albumin. Reported half-life of roughly 6–8 days, with IGF-1 elevation persisting up to two weeks after a single dose.
• CJC-1295 without DAC — often called Mod GRF(1-29). The same stabilized peptide without the albumin-binding modification, with a half-life measured in minutes — a fundamentally different profile despite the shared name.

Learn more in our full CJC-1295 research guide.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide researched as a selective agonist of the ghrelin receptor (GHS-R1a) — one of the two natural pathways commanding pituitary GH release. Developed in the late 1990s by Novo Nordisk (as NNC 26-0161), it was described in its landmark 1998 paper as “the first selective growth hormone secretagogue.”

Its five amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2) incorporate non-natural residues that give it stability and receptor selectivity. It belongs to the growth hormone secretagogue (GHS) family — peptides that mimic ghrelin, the stomach-derived hormone discovered in 1999, at its receptor.

Ipamorelin’s defining research claim is selectivity: at doses that strongly stimulate GH release, it was reported to produce minimal stimulation of ACTH, cortisol, prolactin, or aldosterone — hormones that earlier secretagogues (GHRP-6, GHRP-2, hexarelin) released alongside GH, confounding their research use.

Learn more in our full ipamorelin research guide.

Two Receptors, One Gland

The core distinction is anatomical: both compounds converge on the same cells — the somatotrophs of the anterior pituitary — through entirely separate receptor systems.

CJC-1295 acts on the GHRH receptor (GHRHR), the canonical hypothalamic command pathway. GHRH binding activates intracellular cAMP signaling in somatotrophs — and because this is the receptor the body itself uses, the somatostatin-mediated negative-feedback loops stay engaged. A 2006 human study reported that pulsatile GH secretion persisted during continuous stimulation, with increased trough and mean GH rather than flat output.

Ipamorelin acts on the ghrelin receptor (GHS-R1a) — a receptor discovered through synthetic secretagogues before its natural ligand, ghrelin, was identified in 1999. GHS-R1a signaling runs primarily through the Gq/PLC/calcium pathway rather than cAMP, and it acts at two levels: directly on pituitary somatotrophs and upstream in the hypothalamus, where it modulates GHRH and somatostatin tone.

Because the two receptors use different intracellular cascades, stimulating both engages two complementary release mechanisms — the molecular basis for the synergy literature discussed below.

Key Takeaway: These are not two versions of the same tool. CJC-1295 probes the body’s primary hypothalamic GH command (GHRHR → cAMP), while ipamorelin probes the parallel ghrelin system (GHS-R1a → calcium signaling) at both pituitary and hypothalamic levels.

Pharmacokinetics Compared

The most dramatic difference between the two compounds is not receptor or selectivity — it is how long they last, and this is where the DAC/non-DAC distinction becomes critical.

CJC-1295 DAC was a feat of half-life engineering: the maleimide group binds the peptide to endogenous serum albumin, shielding it from renal clearance and enzymatic degradation. In the 2006 human study, the reported half-life was approximately 6–8 days, with dose-dependent GH elevations for six or more days and IGF-1 elevation for 9–11 days after a single administration — a minutes-long hormonal signal turned into a week-long research tool.

CJC-1295 without DAC (Mod GRF 1-29) and ipamorelin, by contrast, are both short-acting. Without the albumin tether, the stabilized GHRH peptide is cleared in minutes — and ipamorelin, a small pentapeptide, operates on a similarly brief timescale, producing discrete, short-lived GH pulses rather than sustained elevation.

This matters for interpreting the literature: findings from the DAC form do not transfer to the non-DAC form, and much informal discussion conflates the two. When evaluating any claim about either compound, the first question is always which pharmacokinetic form was studied.

The Synergy Literature

One of the most replicated findings in GH-axis research is the synergy between GHRH-pathway and ghrelin-pathway stimulation. Co-stimulating both receptors releases GH supra-additively — together producing more GH than the sum of either pathway alone.

This is a property of the two pathways, documented across many compound pairings — GHRH with GHRP-6, GHRP-2, hexarelin, and later ipamorelin — in animal and human studies stretching back to the 1980s, before either compound in this comparison existed. It is why CJC-1295 and ipamorelin are so frequently discussed together: they are the two most selectivity-optimized tools for probing each arm of the interaction.

But an important line must be drawn: the synergy literature describes pathway interactions studied across many compound pairings. It does not constitute a validated protocol for any specific combination, and the combined regimens discussed in non-scientific contexts have not been tested in formal clinical trials.

Selectivity: Ipamorelin’s Design Story

Ipamorelin’s story is best understood as a deliberate correction to the compounds that came before it.

The first-generation secretagogues — GHRP-6, GHRP-2, hexarelin — were potent GH releasers but noisy ones: research reported they also stimulated ACTH, cortisol, aldosterone, and prolactin. For investigators studying GH-specific biology, these off-target effects were confounders.

Novo Nordisk’s chemistry program set out to separate the signals. The result, described in the landmark 1998 paper, was ipamorelin: GH-releasing potency comparable to GHRP-6 with markedly lower ACTH and cortisol stimulation, and subsequently confirmed sparing of prolactin and aldosterone — the first selective growth hormone secretagogue, valued for the cleanest GH signal in its class.

Evidence Gaps

Both compounds share a common limitation: the published evidence is thin relative to the attention they receive.

First, the human evidence for CJC-1295 is short mid-2000s pharmacology in healthy adults. No long-term human study has been published, and no trial has evaluated body-composition, performance, or disease-related endpoints.

Second, ipamorelin’s selectivity findings were established mainly in animal models and short human pharmacology studies, plus its early-phase postoperative-recovery program. No published study has tested it for body-composition or long-term musculoskeletal endpoints in humans.

Third, the synergy literature describes pathway interactions, not validated protocols for specific combinations — yet much informal discussion centers on combined regimens.

Short pharmacology studies of discontinued compounds are not the same as established evidence bases, and enthusiasm around both compounds runs well ahead of what the literature supports.

Regulatory Status

The regulatory positions of both compounds can be stated plainly:

• Neither compound is FDA approved for any indication, and no drug product containing either has been approved anywhere as a medicine.
• Both development programs were discontinued — ConjuChem’s CJC-1295 program after early-phase human studies in the mid-2000s, and Novo Nordisk’s ipamorelin program after early-phase studies, including the postoperative-ileus investigation.
• Both fall within broad prohibited categories in sports anti-doping frameworks; athletes should check current anti-doping rules, as peptide categories are broad and updated regularly.

Regulatory developments do not change the underlying evidence base: the human data for both compounds consists of early-phase studies only.

Frequently Asked Questions

What is the core difference between the two compounds?

Both stimulate pituitary growth hormone release, but through different receptors. CJC-1295 activates the GHRH receptor — the hypothalamic command pathway, using cAMP signaling. Ipamorelin activates the ghrelin receptor (GHS-R1a) — a separate system using calcium-based signaling at both pituitary and hypothalamic levels.

What is DAC, and why does it matter?

DAC (Drug Affinity Complex) is the albumin-binding modification on the original CJC-1295 design, extending its half-life to roughly a week. CJC-1295 without DAC (Mod GRF 1-29) is the same peptide without the tether, cleared in minutes. Findings do not transfer between the two forms.

Why are they so often studied together?

Because the GHRH and ghrelin pathways release GH synergistically — one of the most replicated findings in GH-axis research, documented across many compound pairings since the 1980s. The synergy is a property of the pathways, not a validated protocol for any specific combination.

Is ipamorelin more selective than other secretagogues?

The published research supports this as its defining claim. Compared with GHRP-6, GHRP-2, and hexarelin, ipamorelin released GH with comparable potency while producing markedly less stimulation of ACTH, cortisol, prolactin, and aldosterone.

Do they preserve natural GH pulsatility?

Both have been reported to amplify the body’s natural episodic GH pulses rather than replacing them with continuous output. CJC-1295 preserved pulsatile secretion during sustained stimulation in a 2006 human study, and GHS compounds are reported to increase pulse amplitude while retaining the underlying rhythm.

Are either of them FDA approved?

No. Neither is FDA approved for any indication, and both development programs were discontinued after early-phase studies. Neither is available as an approved medicine anywhere.

The Bottom Line

CJC-1295 and ipamorelin are complementary probes of the two natural GH-release pathways — the hypothalamic GHRH system and the ghrelin system — and their scientific value lies in what they reveal about those pathways: receptor pharmacology, pulsatile physiology, half-life engineering, and one of the most replicated synergy phenomena in endocrine research.

The pharmacology findings are genuinely interesting. But both programs were discontinued after early-phase work, the human evidence is limited to short studies, the DAC/non-DAC distinction is routinely blurred, and the synergy literature describes pathway interactions rather than validated combinations. For GH-axis and secretagogue-pharmacology researchers, the CJC-1295/ipamorelin literature remains a meaningful — if historically bounded — area of study.

If your research extends beyond the GH axis, our guides on BPC-157, TB-500, KPV, MOTS-c, Semax, Melanotan II, and GHK-Cu cover tissue repair, metabolic, cognitive, and skin-biology research areas.

Explore CJC-1295 & Ipamorelin

Learn more about CJC-1295 and Ipamorelin and explore our research-focused peptides at Vonox Labs: CJC-1295 and Ipamorelin

Research. Test. Learn.

Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not intended for human or veterinary consumption. This information is provided for educational purposes only and is not medical advice.

Scientific References

• Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/ (Single injections of the DAC form in healthy adults; dose-dependent GH increases for 6+ days and IGF-1 elevation for 9–11 days; reported half-life ~6–8 days.)
• Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. https://pubmed.ncbi.nlm.nih.gov/17018654/ (GH pulsatility preserved during sustained CJC-1295 stimulation; trough GH rose 7.5-fold, mean GH 46%, IGF-1 45%.)
• Jette L, Leger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. https://pubmed.ncbi.nlm.nih.gov/15817669/ (Preclinical characterization of the albumin-binding DAC design.)
• Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. https://pubmed.ncbi.nlm.nih.gov/9849822/ (Landmark characterization: GH potency comparable to GHRP-6 in rats with minimal ACTH/cortisol stimulation.)
• Smith RG. Development of growth hormone secretagogues. Endocr Rev. 2005;26(3):346-60. https://pubmed.ncbi.nlm.nih.gov/15814848/ (Review of the GHS class covering ghrelin-receptor pharmacology, selectivity across secretagogues, and clinical development programs.)
• Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-29. https://pubmed.ncbi.nlm.nih.gov/9893708/ (Review of the secretagogue class and the GHRH/GHRP synergy in GH release — the pathway interaction relevant to CJC-1295 + ipamorelin research.)